Comparative tolerability of treatments for acute migraine: A network meta-analysis

Cephalalgia

Volumn 37, Issue 10, 2017, Pages 965-978

  Thorlund, Kristian ^a,b   Toor, Kabirraaj ^b,c   Wu, Ping ^b   Chan, Keith ^b,c   Druyts, Eric ^b   Ramos, Elodie ^d   Bhambri, Rahul ^d   Donnet, Anne ^e   Stark, Richard ^f,g   Goadsby, Peter J ^h  

^a MCMASTER UNIVERSITY   (Canada)

^b Redwood Outcomes   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d Pfizer Ltd   (United States)

^e TIMONE HOSPITAL   (France)

^f ALFRED HOSPITAL   (Australia)

^g MONASH UNIVERSITY   (Australia)

^h WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

adverse events; ergotamines; Migraine; non steroidal anti inflammatory drugs; safety; tolerability; triptans

Indexed keywords

ALMOTRIPTAN; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ELETRIPTAN; ERGOTAMINE; FROVATRIPTAN; IBUPROFEN; NAPROXEN; NARATRIPTAN; PARACETAMOL; PLACEBO; RIZATRIPTAN; SUMATRIPTAN; TRIPTAN DERIVATIVE; ZOLMITRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; TRYPTAMINE DERIVATIVE;

ACUTE DISEASE; COMPARATIVE EFFECTIVENESS; DIZZINESS; DRUG TOLERABILITY; FATIGUE; HUMAN; MIGRAINE; NAUSEA; NETWORK META-ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOMNOLENCE; SYSTEMATIC REVIEW (TOPIC); THORAX PAIN; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; CLINICAL TRIAL (TOPIC); COMBINATION DRUG THERAPY; COMPARATIVE STUDY; META ANALYSIS; PROCEDURES;

ACUTE DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; MIGRAINE DISORDERS; NAPROXEN; SUMATRIPTAN; TREATMENT OUTCOME; TRYPTAMINES;

EID: 85029003148     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102416660552     Document Type: Review

References (144)

1. Goadsby PJ, Lipton RB, Ferrari MD,. Migraine-Current understanding and treatment. N Engl J Med 2002; 346: 257-270.
2. Lipton RB, Hamelsky SW, Kolodner KB, et al. Migraine, quality of life, and depression: A population-based case-control study. Neurology 2000; 55: 629-635.
3. Stokes M, Becker WJ, Lipton RB, et al. Cost of health care among patients with chronic and episodic migraine in Canada and the USA: Results from the International Burden of Migraine Study (IBMS). Headache 2011; 51: 1058-1077.
4. Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine-Revised report of an EFNS task force. Eur J Neurol 2009; 16: 968-981.
5. Goadsby PJ, Sprenger T,. Current practice and future directions in the prevention and acute management of migraine. Lancet Neurol 2010; 9: 285-298.
6. Thorlund K, Mills EJ, Wu P, et al. Comparative efficacy of triptans for the abortive treatment of migraine: A multiple treatment comparison meta-analysis. Cephalalgia 2014; 34: 258-267.
7. Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet 2001; 358: 1668-1675.
8. Saper JR, Silberstein S,. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache 2006; 46 (Suppl 4): S171-S181.
9. Saper J, Dahlof C, So Y, et al. Rofecoxib in the acute treatment of migraine: A randomized controlled clinical trial. Headache 2006; 46: 264-275.
10. Mills EJ, Bansback N, Ghement I, et al. Multiple treatment comparison meta-analyses: a step forward into complexity. Clin Epidemiol 2011; 3: 193-202.
11. Mills EJ, Ioannidis JP, Thorlund K, et al. How to use an article reporting a multiple treatment comparison meta-analysis. JAMA 2012; 308: 1246-1253.
12. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations. Ann Intern Med 2015; 162: 777-784.
13. Sumatriptan-An oral dose-defining study. The Oral Sumatriptan Dose-Defining Study Group. Eur Neurol 1991; 31: 300-305.
14. Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. The Oral Sumatriptan International Multiple-Dose Study Group. Eur Neurol 1991; 31: 306-313.
15. Acute treatment of migraine attacks: Efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group. Cephalalgia 1999; 19: 232-240.
16. Brandes JL, Kudrow D, Stark SR, et al. Sumatriptan-naproxen for acute treatment of migraine: A randomized trial. JAMA 2007; 297: 1443-1454.
17. Cutler N, Mushet GR, Davis R, et al. Oral sumatriptan for the acute treatment of migraine: evaluation of three dosage strengths. Neurology 1995; 45 (8 Suppl 7): S5-S9.
18. Dahlof CJM, Davis K, Loftus J, et al. A comparison of preference for and efficacy of tablet formulations of sumatriptan (50 mg and 100 mg), naratriptan (2.5 mg), rizatriptan (10 mg), and zolmitriptan (2.5 mg) in the acute treatment of migraine. J Headache Pain 2004; 5: 115-122.
19. Dahlof CG, Hauge AW, Olesen J,. Efficacy and safety of tonabersat, a gap-junction modulator, in the acute treatment of migraine: A double-blind, parallel-group, randomized study. Cephalalgia 2009; 29 Suppl 2: 7-16.
20. Diener HC, Gendolla A, Gebert I, et al. Almotriptan in migraine patients who respond poorly to oral sumatriptan: A double-blind, randomized trial. Headache 2005; 45: 874-882.
21. Diener HC, Pfaffenrath V, Pageler L, et al. The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: A multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 2005; 25: 776-787.
22. Dowson AJ, Charlesworth BR,. Patients with migraine prefer zolmitriptan orally disintegrating tablet to sumatriptan conventional oral tablet. Int J Clin Pract 2003; 57: 573-576.
23. Dowson AJ, Massiou H, Aurora SK,. Managing migraine headaches experienced by patients who self-report with menstrually related migraine: A prospective, placebo-controlled study with oral sumatriptan. J Headache Pain 2005; 6: 81-87.
24. Dowson AJ, Massiou H, Lainez JM, et al. Almotriptan is an effective and well-tolerated treatment for migraine pain: Results of a randomized, double-blind, placebo-controlled clinical trial. Cephalalgia 2002; 22: 453-461.
25. Friedman BW, Solorzano C, Esses D, et al. Treating headache recurrence after emergency department discharge: A randomized controlled trial of naproxen versus sumatriptan. Ann Emergency Med 2010; 56: 7-17.
26. Gallagher RM, Dennish G, Spierings EL, et al. A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine. Headache 2000; 40: 119-128.
27. Goadsby PJ, Ferrari MD, Olesen J, et al. Eletriptan in acute migraine: A double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee. Neurology 2000; 54: 156-163.
28. Goadsby PJ, Zagami AS, Donnan GA, et al. Oral sumatriptan in acute migraine. Lancet 1991; 338: 782-783.
29. Goldstein J, Ryan R, Jiang K, et al. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group. Headache 1998; 38: 737-747.
30. Goldstein J, Silberstein SD, Saper JR, et al. Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: Results from the ASSET trial. Headache 2005; 45: 973-982.
31. Gruffyd-Jones K, Kies B, Middleton A, et al. Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: A randomized, double-blind, international study. Eur J Neuro 2001; 8: 237-245.
32. Havanka H, Dahlof C, Pop PH, et al. Efficacy of naratriptan tablets in the acute treatment of migraine: A dose-ranging study. Naratriptan S2WB2004 Study Group. Clin Ther 2000; 22: 970-980.
33. Ishkanian G, Blumenthal H, Webster CJ, et al. Efficacy of sumatriptan tablets in migraineurs self-described or physician-diagnosed as having sinus headache: A randomized, double-blind, placebo-controlled study. Clin Ther 2007; 29: 99-109.
34. Jelinski SE, Becker WJ, Christie SN, et al. Pain free efficacy of sumatriptan in the early treatment of migraine. Can J Neurol Sci 2006; 33: 73-79.
35. Kolodny A, Polis A, Battisti WP, et al. Comparison of rizatriptan 5 mg and 10 mg tablets and sumatriptan 25 mg and 50 mg tablets. Cephalalgia 2004; 24: 540-546.
36. Kudrow D, Thomas HM, Ruoff G, et al. Valdecoxib for treatment of a single, acute, moderate to severe migraine headache. Headache 2005; 45: 1151-1162.
37. Landy S, Savani N, Shackelford S, et al. Efficacy and tolerability of sumatriptan tablets administered during the mild-pain phase of menstrually associated migraine. Int J Clin Pract 2004; 58: 913-919.
38. Loder E, Brandes JL, Silberstein S, et al. Preference comparison of rizatriptan ODT 10-mg and sumatriptan 50-mg tablet in migraine. Headache 2001; 41: 745-753.
39. Mathew NT, Schoenen J, Winner P, et al. Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg. Headache 2003; 43: 214-222.
40. Misra M, Sharma T, Kalra J, et al. Comparative efficacy and tolerability of sumatriptan, ergotamine, naproxen and rizatriptan in moderate to severe acute attack of migraine. JK Sci 2010; 12: 175-179.
41. Myllyla VV, Havanka H, Herrala L, et al. Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: Comparable effect in a double-blind, randomized, controlled, parallel-group study. Headache 1998; 38: 201-207.
42. Nappi G, Sicuteri F, Byrne M, et al. Oral sumatriptan compared with placebo in the acute treatment of migraine. J Neurol 1994; 241: 138-144.
43. Nett R, Landy S, Shackelford S, et al. Pain-free efficacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine. Obstet Gynecol 2003; 102: 835-842.
44. Pascual J, Bussone G, Hernandez JF, et al. Comparison of preference for rizatriptan 10-mg wafer versus sumatriptan 50-mg tablet in migraine. Eur Neurol 2001; 45: 275-283.
45. Pfaffenrath V, Cunin G, Sjonell G, et al. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: Defining the optimum doses of oral sumatriptan. Headache 1998; 38: 184-190.
46. Pini LA, Fabbri L, Cavazzuti L,. Efficacy and safety of sumatriptan 50 mg in patients not responding to standard care, in the treatment of mild to moderate migraine. The Sumatriptan 50 mg Italian Study Group. Int J Clin Pharmacol Res 1999; 19: 57-64.
47. Sandrini G, Farkkila M, Burgess G, et al. Eletriptan vs sumatriptan: A double-blind, placebo-controlled, multiple migraine attack study. Neurology 2002; 59: 1210-1217.
48. Sargent J, Kirchner JR, Davis R, et al. Oral sumatriptan is effective and well tolerated for the acute treatment of migraine: Results of a multicenter study. Neurology 1995; 45 (8 Suppl 7): S10-S14.
49. Savani N, Brautaset NJ, Reunanen M, et al. A double-blind placebo-controlled study assessing the efficacy and tolerability of 50 mg sumatriptan tablets in the acute treatment of migraine. Sumatriptan Tablets S2CM07 Study Group. Int J Clin Pract Suppl 1999; 105: 7-15.
50. Sheftell FD, Dahlof CG, Brandes JL, et al. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets. Clin Ther 2005; 27: 407-417.
51. Smith TR, Sunshine A, Stark SR, et al. Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache 2005; 45: 983-991.
52. SMT-06-91. Double blind, placebo-controlled, cross-over study to assess the safety and efficacy of repeated oral doses of sumatriptan (GR43175C 100 mg (plus two optional oral doses of sumatriptan (GR43175C) 100 mg) in the acute treatment of migraine. 2006.
53. Spierings EL, Gomez-Mancilla B, Grosz DE, et al. Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: A double-blind, randomized, parallel-group, optimum-dose comparison. Arch Neurol 2001; 58: 944-950.
54. SUM20033. A randomized, double-blind, placebo-controlled, in-clinic pilot study to investigate the efficacy and tolerability of 100mh sumatriptan administered as a film-coated, fast disintegrating tablet. 2005.
55. SUM40311. A randomized, double-blind, placebo-controlled, single-attack, parallel-group evaluation of the efficacy of sumatriptan 100mg tablets versus placebo in the treatment of self-described and/or physician-diagnosed sinus headaches that meet International Headache Society (IHS) criteria for migraine headache. 2005.
56. SUMA4014. A double-blind, placebo-controlled, parallel group study to evaluate the efficacy of a second sumatriptan succinate tablet (25 or 50 mg) in the acute treatment of migraine. 2005.
57. Tepper SJ, Cady R, Dodick D, et al. Oral sumatriptan for the acute treatment of probable migraine: First randomized, controlled study. Headache 2006; 46: 115-124.
58. Tfelt-Hansen P, Bach FW, Daugaard D, et al. Treatment with sumatriptan 50 mg in the mild phase of migraine attacks in patients with infrequent attacks: A randomised, double-blind, placebo-controlled study. J Headache Pain 2006; 7: 389-394.
59. Tfelt-Hansen P, Henry P, Mulder LJ, et al. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995; 346: 923-926.
60. Tfelt-Hansen P, Teall J, Rodriguez F, et al. Oral rizatriptan versus oral sumatriptan: A direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group. Headache 1998; 38: 748-755.
61. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group. A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. Eur Neurol 1991; 31: 314-322.
62. White WB, Derosier FJ, Thompson AH, et al. Evaluation of the migraine treatment sumatriptan/naproxen sodium on blood pressure following long-term administration. J Clin Hypertens 2011; 13: 910-916.
63. Allais G, Bussone G, D'Andrea G, et al. Almotriptan 12.5 mg in menstrually related migraine: A randomized, double-blind, placebo-controlled study. Cephalalgia 2011; 31: 144-151.
64. Bartolini M, Giamberardino MA, Lisotto C, et al. A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine. J Headache Pain 2011; 12: 361-368.
65. Dahlof C, Tfelt-Hansen P, Massiou H, et al. Dose finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine. Neurology 2001; 57: 1811-1817.
66. Diez FI, Straube A, Zanchin G,. Patient preference in migraine therapy. A randomized, open-label, crossover clinical trial of acute treatment of migraine with oral almotriptan and rizatriptan. J Neurol 2007; 254: 242-249.
67. Goadsby PJ, Massiou H, Pascual J, et al. Almotriptan and zolmitriptan in the acute treatment of migraine. Acta Neurol Scand 2007; 115: 34-40.
68. Goadsby PJ, Zanchin G, Geraud G, et al. Early vs. non-early intervention in acute migraine-'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia 2008; 28: 383-391.
69. Lainez MJ, Galvan J, Heras J, et al. Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy. Eur J Neurol 2007; 14: 269-275.
70. Mathew NT, Finlayson G, Smith TR, et al. Early intervention with almotriptan: Results of the AEGIS trial (AXERT Early Migraine Intervention Study). Headache 2007; 47: 189-198.
71. Pascual J, Falk RM, Piessens F, et al. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: Results of a large, randomized, double-blind, placebo-controlled study. Cephalalgia 2000; 20: 588-596.
72. Brandes JL, Kudrow D, Cady R, et al. Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing. Cephalalgia 2005; 25: 735-742.
73. Diener HC, Barbanti P, Dahlof C, et al. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: Results from a phase II study. Cephalalgia 2011; 31: 573-584.
74. Diener HC, Jansen JP, Reches A, et al. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: A multicentre, randomised, double-blind, placebo-controlled comparison. Eur Neurol 2002; 47: 99-107.
75. Eletriptan Steering Committee in Japan. Efficacy and safety of eletriptan 20 mg, 40 mg and 80 mg in Japanese migraineurs. Cephalalgia 2002; 22: 416-423.
76. Farkkila M, Olesen J, Dahlof C, et al. Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. Cephalalgia 2003; 23: 463-471.
77. Garcia-Ramos G, MacGregor EA, Hilliard B, et al. Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine. Cephalalgia 2003; 23: 869-876.
78. Lainez MJ, Evers S, Kinge E, et al. Preference for rizatriptan 10-mg wafer vs. eletriptan 40-mg tablet for acute treatment of migraine. Cephalalgia 2006; 26: 246-256.
79. Olesen J, Diener HC, Schoenen J, et al. No effect of eletriptan administration during the aura phase of migraine. Eur J Neurol 2004; 11: 671-677.
80. Sheftell F, Ryan R, Pitman V,. Efficacy, safety, and tolerability of oral eletriptan for treatment of acute migraine: A multicenter, double-blind, placebo-controlled study conducted in the United States. Headache 2003; 43: 202-213.
81. Stark R, Dahlof C, Haughie S, et al. Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: Results of a phase III, multicentre, placebo-controlled study across three attacks. Cephalalgia 2002; 22: 23-32.
82. Steiner TJ, Diener HC, MacGregor EA, et al. Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia 2003; 23: 942-952.
83. Rapoport A, Ryan R, Goldstein J, et al. Dose range-finding studies with frovatriptan in the acute treatment of migraine. Headache 2002; 42 (Suppl 2): S74-S83.
84. Savi L, Omboni S, Lisotto C, et al. Efficacy of frovatriptan in the acute treatment of menstrually related migraine: Analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study versus rizatriptan. J Headache Pain 2011; 12: 609-615.
85. Tullo V, Allais G, Ferrari MD, et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine: A double-blind, randomized, multicenter, Italian study. Neuro Sci 2010; 31(Suppl 1): S51-S54.
86. Bomhof M, Paz J, Legg N, et al. Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine. Eur Neurol 1999; 42: 173-179.
87. Klassen A, Elkind A, Asgharnejad M, et al. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study Group. Headache 1997; 37: 640-645.
88. Massiou H, Jamin C, Hinzelin G, et al. Efficacy of oral naratriptan in the treatment of menstrually related migraine. Eur J Neurol 2005; 12: 774-781.
89. Mathew NT, Asgharnejad M, Peykamian M, et al. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group. Neurology 1997; 49: 1485-1490.
90. Stark S, Spierings EL, McNeal S, et al. Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. Headache 2000; 40: 513-520.
91. Ahrens SP, Farmer MV, Williams DL, et al. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group. Cephalalgia 1999; 19: 525-530.
92. Barbanti P, Fofi L, Dall'Armi V, et al. Rizatriptan in migraineurs with unilateral cranial autonomic symptoms: A double-blind trial. J Headache Pain 2012; 13: 407-414.
93. Cady R, Martin V, Mauskop A, et al. Efficacy of rizatriptan 10 mg administered early in a migraine attack. Headache 2006; 46: 914-924.
94. Cady RK, Martin VT, Geraud G, et al. Rizatriptan 10-mg ODT for early treatment of migraine and impact of migraine education on treatment response. Headache 2009; 49: 687-696.
95. Christie S, Gobel H, Mateos V, et al. Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine. Eur Neurol 2003; 49: 20-29.
96. Freitag F, Diamond M, Diamond S, et al. Efficacy and tolerability of coadministration of rizatriptan and acetaminophen vs rizatriptan or acetaminophen alone for acute migraine treatment. Headache 2008; 48: 921-930.
97. Freitag F, Taylor FR, Hamid MA, et al. Elimination of migraine-associated nausea in patients treated with rizatriptan orally disintegrating tablet (ODT): A randomized, double-blind, placebo-controlled study. Headache 2008; 48: 368-377.
98. Gijsman H, Kramer MS, Sargent J, et al. Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine. Cephalalgia 1997; 17: 647-651.
99. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: A randomised, placebo-controlled, parallel-treatment trial. Lancet 2008; 372: 2115-2123.
100. Kramer MS, Matzura-Wolfe D, Polis A, et al. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Rizatriptan Multiple Attack Study Group. Neurology 1998; 51: 773-781.
101. Mannix LK, Savani N, Landy S, et al. Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: Data from two randomized, double-blind, placebo-controlled studies. Headache 2007; 47: 1037-1049.
102. Misra UK, Kalita J, Yadav RK,. Rizatriptan vs. ibuprofen in migraine: A randomised placebo-controlled trial. J Headache Pain 2007; 8: 175-179.
103. Pascual J, Vega P, Diener HC, et al. Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan-Zolmitriptan Study Group. Cephalalgia 2000; 20: 455-461.
104. Savi L, Omboni S, Lisotto C, et al. A double-blind, randomized, multicenter, Italian study of frovatriptan versus rizatriptan for the acute treatment of migraine. J Headache Pain 2011; 12: 219-226.
105. Seeburger JL, Cady RK, Winner P, et al. Rizatriptan for treatment of acute migraine in patients taking topiramate for migraine prophylaxis. Headache 2012; 52: 57-67.
106. Seeburger JL, Taylor FR, Friedman D, et al. Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders. Cephalalgia 2011; 31: 786-796.
107. Teall J, Tuchman M, Cutler N, et al. Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group. Headache 1998; 38: 281-287.
108. Visser WH, Terwindt GM, Reines SA, et al. Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group. Arch Neurol 1996; 53: 1132-1137.
109. Dib M, Massiou H, Weber M, et al. Efficacy of oral ketoprofen in acute migraine: A double-blind randomized clinical trial. Neurology 2002; 58: 1660-1665.
110. Dowson AJ, MacGregor EA, Purdy RA, et al. Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. Cephalalgia 2002; 22: 101-106.
111. Klapper J, Lucas C, Rosjo O, et al. Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia 2004; 24: 918-924.
112. Loder E, Freitag FG, Adelman J, et al. Pain-free rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine: Results of a large double-blind placebo- controlled trial. Curr Med Res Opin 2005; 21: 381-389.
113. Loder E, Silberstein SD, Abu-Shakra S, et al. Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: A randomized, prospective, parallel-group, double-blind, placebo-controlled study. Headache 2004; 44: 120-130.
114. Rapoport AM, Ramadan NM, Adelman JU, et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group. Neurology 1997; 49: 1210-1218.
115. Sakai F, Iwata M, Tashiro K, et al. Zolmitriptan is effective and well tolerated in Japanese patients with migraine: A dose-response study. Cephalalgia 2002; 22: 376-383.
116. Solomon GD, Cady RK, Klapper JA, et al. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group. Neurology 1997; 49: 1219-1225.
117. Spierings EL, Rapoport AM, Dodick DW, et al. Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet. CNS Drugs 2004; 18: 1133-1141.
118. Tuchman M, Hee A, Emeribe U, et al. Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs 2006; 20: 1019-1026.
119. Tullo V, Allais G, Ferrari MD, et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine: A double-blind, randomized, multicenter, Italian study. Neurol Sci 2010; 31 (Suppl 1): S51-S54.
120. Goldstein J, Silberstein SD, Saper JR, et al. Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: Results from a multicenter, double-blind, randomized, parallel-group, single-dose, placebo-controlled study. Headache 2006; 46: 444-453.
121. Lipton RB, Baggish JS, Stewart WF, et al. Efficacy and safety of acetaminophen in the treatment of migraine: Results of a randomized, double-blind, placebo-controlled, population-based study. Arch Intern Med 2000; 160: 3486-3492.
122. Lipton RB, Stewart WF, Ryan RE Jr., et al. Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain: Three double-blind, randomized, placebo-controlled trials. Arch Neurol 1998; 55: 210-217.
123. Prior MJ, Codispoti JR, Fu M,. A randomized, placebo-controlled trial of acetaminophen for treatment of migraine headache. Headache 2010; 50: 819-833.
124. Silberstein SD, Armellino JJ, Hoffman HD, et al. Treatment of menstruation-associated migraine with the nonprescription combination of acetaminophen, aspirin, and caffeine: Results from three randomized, placebo-controlled studies. Clin Ther 1999; 21: 475-491.
125. Misra UK, Jose M, Kalita J,. Rofecoxib versus ibuprofen for acute treatment of migraine: A randomised placebo controlled trial. Postgrad Med J 2004; 80: 720-723.
126. Silberstein S, Tepper S, Brandes J, et al. Randomized, placebo-controlled trial of rofecoxib in the acute treatment of migraine. Neurology 2004; 62: 1552-1557.
127. Wentz AL, Jimenez TB, Dixon RM, et al. A double-blind, randomized, placebo-controlled, single-dose study of the cyclooxygenase-2 inhibitor, GW406381, as a treatment for acute migraine. Eur J Neurol 2008; 15: 420-427.
128. Peroutka SJ, Lyon JA, Swarbrick J, et al. Efficacy of diclofenac sodium softgel 100 mg with or without caffeine 100 mg in migraine without aura: A randomized, double-blind, crossover study. Headache 2004; 44: 136-141.
129. Cady R, Nett R, Dexter K, et al. Treatment of chronic migraine: A 3-month comparator study of naproxen sodium vs SumaRT/Nap. Headache 2014; 54: 80-93.
130. Johnson ES, Ratcliffe DM, Wilkinson M,. Naproxen sodium in the treatment of migraine. Cephalalgia 1985; 5: 5-10.
131. Hakkarainen H, Vapaatalo H, Gothoni G, et al. Tolfenamic acid is as effective as ergotamine during migraine attacks. Lancet 1979; 2: 326-328.
132. Le Jeunne C, Gomez JP, Pradalier A, et al. Comparative efficacy and safety of calcium carbasalate plus metoclopramide versus ergotamine tartrate plus caffeine in the treatment of acute migraine attacks. Eur Neurol 1999; 41: 37-43.
133. Pradalier A, Lanteri-Minet M, Geraud G, et al. The PROMISE study: PROphylaxis of MIgraine with SEglor (dihydroergotamine mesilate) in French primary care. CNS Drugs 2004; 18: 1149-1163.
134. Derosier F, Sheftell F, Silberstein S, et al. Sumatriptan-naproxen and butalbital: A double-blind, placebo-controlled crossover study. Headache 2012; 52: 530-543.
135. Lipton R, Dodick D, Adelman J, et al. Consistency of response to sumatriptan-naproxen sodium in a placebo-controlled, crossover study. Cephalalgia 2009; 29: 826-836.
136. Mannix LK, Martin VT, Cady RK, et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen. Obstet Gynecol 2009; 114: 106-113.
137. Mathew NT, Landy S, Stark S, et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life: Research submissions. Headache 2009; 49: 971-982.
138. Masferrer JL, Zweifel BS, Manning PT, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994; 91: 3228-3232.
139. Mitchell JA, Larkin S, Williams TJ,. Cyclooxygenase-2: Regulation and relevance in inflammation. Biochem Pharmacol 1995; 50: 1535-1542.
140. Lu G, Ades AE,. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004; 23: 3105-3124.
141. Mills EJ, Thorlund K, Ioannidis JP,. Demystifying trial networks and network meta-analysis. BMJ 2013; 346: f2914-f2914.
142. Dias S, Welton N, Sutton A, et al. NICE DSU Technical Support Document 2-A generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trial. 2011.
143. Spiegelhalter DJ, Best NG, Carlin BP, et al. Bayesian measures of model complexity and fit. J R Stat Soc Series B Stat Methodol 2002; 64: 583-639.
144. Tfelt-Hansen P,. A review of evidence-based medicine and meta-analytic reviews in migraine. Cephalalgia 2006; 26: 1265-1274.